Acurx (ACXP) announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 825,085 shares of its common stock at a purchase price of $3.03 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the company will issue unregistered short-term warrants to purchase up to 1,650,170 shares of common stock. The short-term warrants will have an exercise price of $2.78 per share, will be immediately exercisable upon issuance and will expire twenty-four months following the effective date of the registration statement registering the resale of the shares of common stock underlying the short-term warrants. The closing of the offering is expected to occur on or about April 16, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACXP:
- Acurx Pharmaceuticals Secures New Financing to Advance Pipeline
- New to The Street announce re-signing of Acurx Pharmaceuticals
- Acurx: KIPO grantes new patent covering DNA Polymerase IIIC inhibitors
- Acurx price target lowered to $10 from $20 at Alliance Global
- Acurx reports Q4 EPS (73c) vs. ($3.29) last year
